Sugi Predict

Sugi Predict / Compounds / SCHEMBL667246

SCHEMBL667246

SCHEMBL667246

COC(=O)Cn1c(=O)cc[nH]c1=O

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.54
▸ ALDH1A1 P00352 2/20 0.48
▸ HSD17B10 Q99714 2/20 0.48
▸ TSHR P16473 2/20 0.43
▸ JAK2 O60674 1/20 0.43
▸ JAK1 P23458 1/20 0.43
▸ TYK2 P29597 1/20 0.43
▸ JAK3 P52333 1/20 0.43
▸ CDK4 P11802 1/20 0.40
▸ CCND1 P24385 1/20 0.40
▸ CCND2 P30279 1/20 0.40
▸ CCND3 P30281 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ KAT2B Q92831 1/20 0.40
▸ NPC1 O15118 1/20 0.39
▸ DYRK1A Q13627 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13629866 0.81 PDE4A (0.36) KDM4ESMN1; SMN2ALDH1A1NPC1
SCHEMBL2899641 0.79 APEX1 (0.48) KDM4EALDH1A1KMT2A
SCHEMBL7231380 0.75 CDK4 (0.34) KDM4EHSD17B10CDK4CCND1CCND2
SCHEMBL490624 0.73 — —
SCHEMBL7340852 0.72 KDM4E (0.52) KDM4ESMN1; SMN2ALDH1A1HSD17B10TSHR
SCHEMBL1923337 0.72 CYP1A2 (0.44) KDM4ESMN1; SMN2ALDH1A1TSHRJAK2
SCHEMBL5860460 0.72 LMNA (0.49) KDM4ESMN1; SMN2ALDH1A1KMT2ANPC1
SCHEMBL7643580 0.72 SLC9A1 (0.58) KDM4ESMN1; SMN2ALDH1A1HSD17B10TSHR
SCHEMBL4348692 0.72 ADRA1D (0.37) KMT2A
SCHEMBL8064660 0.72 DAO (0.31) KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 823 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014152909-A1 ALTERATION OF GENE EXPRESSION BY SYNTHETIC piRNAs AND BY ALTERATION OF piRNA FUNCTION IBIS BIOSCIENCES, INC. (US) 2014-09-25 — — WO claimed
US-20260138999-A1 REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS BRISTOL MYERS SQUIBB CO (US) 2026-05-21 — — US disclosed
US-12629412-B2 Betacoronavirus mRNA vaccines MODERNATX, INC. (US) 2026-05-19 — — US disclosed
CN-122038302-A Modified T cells and methods of making and using the same 哈佛学院校长同事会 2026-05-15 — — CN disclosed
US-20260132404-A1 MODIFIED OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS ALNYLAM PHARMACEUTICALS, INC. (US) 2026-05-14 — — US disclosed
US-20260130985-A1 NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF ADVANCED RNA VACCINE ARV TECH INC (US) 2026-05-14 — — US disclosed
US-12622960-B2 Varicella zoster virus (VZV) vaccine MODERNATX, INC. (US) 2026-05-12 — — US disclosed
US-20260108595-A1 BETACORONAVIRUS mRNA VACCINES MODERNATX, INC. (US) 2026-04-23 — — US disclosed
EP-4727955-A1 CYSTEINE-SUBSTITUTED RSV-F PROTEINS GlaxoSmithKline Biologicals S.A. (BE) 2026-04-22 — — EP disclosed
US-20260097110-A1 BETACORONAVIRUS mRNA VACCINES MODERNATX, INC. (US) 2026-04-09 — — US disclosed
EP-0960121-A1 PEPTIDE NUCLEIC ACIDS HAVING ENHANCED BINDING AFFINITY, SEQUENCE SPECIFICITY AND SOLUBILITY BUCHARDT, Dorte (DK) 1999-12-01 — — EP disclosed
WO-1998003542-A1 PEPTIDE NUCLEIC ACIDS HAVING ENHANCED BINDING AFFINITY, SEQUENCE SPECIFICITY AND SOLUBILITY BUCHARDT, DORTE (DK) 1998-01-29 — — WO disclosed
EP-0683668-A4 COMPOSITIONS AND METHODS FOR TRANSDERMAL DRUG DELIVERY. AFFYMAX TECH NV (AN) 1997-12-29 — — EP disclosed
EP-0647133-A4 COMPOSITIONS AND METHODS FOR ENHANCED DRUG DELIVERY. AFFYMAX TECH NV (AN) 1997-10-29 — — EP disclosed
EP-0683668-A1 COMPOSITIONS AND METHODS FOR TRANSDERMAL DRUG DELIVERY AFFYMAX TECHNOLOGIES N.V. (AN) 1995-11-29 — — EP disclosed
EP-0647133-A1 COMPOSITIONS AND METHODS FOR ENHANCED DRUG DELIVERY AFFYMAX TECHNOLOGIES N.V. (AN) 1995-04-12 — — EP disclosed
WO-1994017792-A2 COMPOSITIONS AND METHODS FOR TRANSDERMAL DRUG DELIVERY AFFYMAX TECHNOLOGIES N.V. (AN) 1994-08-18 — — WO disclosed
WO-1993025197-A1 COMPOSITIONS AND METHODS FOR ENHANCED DRUG DELIVERY AFFYMAX TECHNOLOGIES N.V. (AN) 1993-12-23 — — WO disclosed
WO-1992019637-A1 OLIGONUCLEOTIDE ANALOGS CONTAINING THIOFORMACETAL LINKAGES GILEAD SCIENCES, INC. (US) 1992-11-12 — — WO disclosed
WO-1991006629-A1 OLIGONUCLEOTIDE ANALOGS WITH NOVEL LINKAGES GILEAD SCIENCES, INC. (US) 1991-05-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260097110-A1 BETACORONAVIRUS mRNA VACCINES RNMT, RNGTT, METTL16 KDM4E 1943/4885SMN1; SMN2 2736/4885ALDH1A1 4724/4885
US-20260138999-A1 REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS RNGTT, CDA, DCTD KDM4E 3277/4885SMN1; SMN2 453/4885ALDH1A1 2053/4885
US-12629412-B2 Betacoronavirus mRNA vaccines RNMT, RNGTT, METTL16 KDM4E 1991/4885SMN1; SMN2 2789/4885ALDH1A1 4705/4885
US-20260132404-A1 MODIFIED OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS RNASEL, NSUN2, ADAR KDM4E 1669/4885SMN1; SMN2 165/4885ALDH1A1 4415/4885
US-20260108595-A1 BETACORONAVIRUS mRNA VACCINES RNMT, METTL16, NSUN2 KDM4E 2008/4885SMN1; SMN2 2126/4885ALDH1A1 4565/4885
US-12622960-B2 Varicella zoster virus (VZV) vaccine NSUN2, RNMT, RNGTT KDM4E 260/4885SMN1; SMN2 3205/4885ALDH1A1 4802/4885
US-20260130985-A1 NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF UPF1, NSUN2, CD4 KDM4E 1144/4885SMN1; SMN2 180/4885ALDH1A1 4843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.